Access to Innovative Medicines Tip SheetDeveloped by the Preventive Cardiovascular Nurses Association, this is a critical reference includes tips and resources for how to navigate administrative systems, maximize efficiency of the prior authorization process, and improve nurse job satisfaction and adherence/patient outcomes. Particularly focused on PCSK9, NOAC and new heart failure therapies.
Improving Medication Adherence in Cardiometabolic Disease Practical and Regulatory ImplicationsThis paper summarizes the scope of CVD nonadherence, describes key U.S. Food and Drug Administration initiatives, and identifies potential targets for improvement.
Grand rounds – Overcoming Barriers to Medication Adherence for Chronic Diseases (CDC) Speakers discuss research, interventions, education, and emerging tools and technologies that may help overcome barriers to medication non-adherence.
ABC Prior Authorization Resource Kits The Prior Authorization Work Group for the ABC Access to Care initiative has developed resources to help cardiology practices better respond to the administrative needs of the current prior authorization process and improve patient access to appropriate, evidence-based therapies. These Resource Kits have been uniquely designed for cardiology practices working with underserved minority patients. The Resource Kits have also been constructed to serve physicians, nurses, and other staff members that interact with PA.
PCNA Heart Healthy Toolbox This extensive resource includes background information and strategies for professionals, plus focused sheets to share with patients regarding healthy eating, exercise and total health.
PCNA Access to Innovative Medicines: Professional and Patient Resources Innovative therapies to prevent and treat heart disease and stroke fill an important health care need for many. The resources for health care providers both providers and their patients focus on strategies and tips to help patients get the medication they need—and to adhere to prescribed therapies to improve patient outcomes.
Cardiologist’s Perceptions of Access to New Therapies 2016 survey (ACC)Revealed that implementing new therapies is a problem, requiring more professional time due to administrative barriers; The top two barriers to trying new therapies are a) cost and b) prior authorization documentation; Cardiologists feel very favorably about prescribing new medications. And, cardiologists would be much more likely to prescribe appropriate new therapies if they did not experience delays/denials.
Provider survey on challenges in prescribing PCSK9 (NLA)A healthcare provider’s competency in dyslipidemia management requires a thorough understanding of existing and emerging evidence-based therapies that they can utilize in clinical practice. Watch these short videos and learn about the NLA‘s provider survey as well as some of the preliminary results found about the challenges to access PCSK9 therapy.
FOCUS analysis (FH Foundation)Shows that regardless of medical need, prescriptions for PCSK9 inhibitors are being rejected at high rates.
Support of legislation such as California’s Senate Bill 866 (NLA)The California Department of Managed Health Care and the Department of Insurance developed a mandatory Prescription Drug Prior Authorization Request Form.
The Prior Authorization Coalition17 members including ACC, AMA, American Pharmacists Association, and Medical Group Management Association. Medical Group Management Association, state medical associations/societies (OH, MN, WA, NC) is calling for an industry-wide reassessment of prior authorization, following a set of 21 principles.
PCSK9i Patient Access Prior Authorization Out-of-Of Pocket CostArticle published in JAMA Cardiology evaluating patient access to PCSK9i among those prescribed therapy using pharmacy transaction data.
Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab Pooled Data From Randomized TrialsJennifer G. Robinson, MD, MPH, Robert S. Rosenson, MD, Michel Farnier, MD, PHD, Umesh Chaudhari, MD, William J. Sasiela, PHD, Laurence Merlet, MS, Kathryn Miller, MS, John J.P. Kastelein, MD, PHDh.